Description
Cagrilintide is a long-acting analog of the endogenous hormone amylin, developed as a therapeutic peptide for obesity and metabolic disorders. By activating amylin and calcitonin receptors, it slows gastric emptying, promotes satiety, and reduces food intake. Unlike native amylin, which has a short half-life, Cagrilintide is engineered for extended activity, enabling once-weekly administration. It is being investigated both as monotherapy and in combination with GLP-1 receptor agonists for synergistic weight loss and metabolic improvements.
*Cagrilintide is an experimental research compound and is not FDA-approved for human use.
Reviews
There are no reviews yet.